TB-500 (Thymosin Beta-4): sourcing, documentation and price
A research-supply overview of TB-500 (thymosin beta-4), covering its identifiers, the pathway it is studied against, and the documentation and pricing considerations for laboratory sourcing.
TB-500 is the research name for a synthetic 17–23 fragment of thymosin beta-4, a naturally occurring actin-binding peptide. Synonyms in the literature include thymosin beta-4 fragment 17–23, Tβ4(17–23), and the N-acetylated, C-amidated form sometimes written as Ac-LKKTETQ-NH2. It is classed as a synthetic peptide fragment, supplied as a lyophilised powder for laboratory use. The evidence block for this page does not provide a full sequence, molecular formula, or molecular weight, so none are stated here; those values should be taken from the certificate of analysis accompanying a specific lot rather than from a general article.
The work indexed in the evidence centres on a Phase 1/2 trial record evaluating the safety and tolerability of TB-500 versus placebo in adults with stable atherosclerotic cardiovascular disease (ASCVD), with exploratory endpoints assessing vascular function and inflammation biomarkers [1]. That record is the only source available for this page, and it is a trial record rather than a completed peer-reviewed report; every statement below is bounded by what that record contains.
Research Studies
TB-500 and safety and tolerability in stable ASCVD
The indexed record describes a Phase 1/2 trial comparing TB-500 against placebo in adults with stable ASCVD [1]. The primary framing of that study is safety and tolerability, not efficacy. In practical sourcing terms this matters: a compound whose indexed human record is an early-phase tolerability study is a compound for which the published human dataset is thin, and a supplier's documentation should be read with that in mind.
TB-500 and vascular function endpoints in stable ASCVD
Vascular function is listed among the exploratory endpoints of the same trial record [1]. Exploratory endpoints are hypothesis-generating by design; they are not powered to establish an effect, and the record does not report results. No claim about vascular function in humans can be drawn from this source beyond the fact that it was measured as an exploratory variable.
TB-500 and inflammation biomarkers in stable ASCVD
Inflammation biomarkers are the second exploratory endpoint named in the record [1]. As with vascular function, the record establishes that these biomarkers were assessed in adults with stable ASCVD; it does not report outcomes. Any statement that TB-500 changed an inflammatory marker in humans would go beyond the evidence available here and is therefore not made.
TB-500 and the study population: adults with stable ASCVD
The population in the indexed record is adults with stable atherosclerotic cardiovascular disease [1]. This is a specific clinical population, not healthy volunteers and not a general population. Effects observed in one population are not transferable to another without separate study, and the record does not report effects at all — it reports a study design.
TB-500 and the placebo comparator
The record specifies a placebo comparator [1]. Placebo-controlled design is the standard against which tolerability signals are read in early-phase work. For a sourcing page, the relevant point is that the indexed human evidence for TB-500 is a placebo-controlled early-phase record and nothing broader.
TB-500 and phase of development
The indexed study is Phase 1/2 [1]. Phase 1/2 sits at the boundary between first-in-human tolerability work and preliminary activity assessment. Compounds at this stage typically have limited human exposure data, and the documentation a laboratory should expect from a supplier — identity, purity, and lot-specific analytical data — carries correspondingly more weight.
TB-500 and the limits of the indexed evidence
Only one source is available for this page, and it is a trial record rather than a results publication [1]. There is no animal study, no in vitro study, and no completed human dataset in the evidence block. Where a claim is not supported by that record, it has been left out rather than inferred. This is stated plainly because a sourcing decision should rest on what is documented, not on what is assumed.
TB-500 documentation and what a lot record should contain
Because the indexed human evidence is an early-phase record [1], the practical burden falls on lot documentation. A research-use lot record should let a laboratory verify identity and purity independently. The table below sets out the categories of documentation and what each is used for; it does not assign values, because values are lot-specific and are not given in the evidence block.
| Document | What it establishes | Why it matters for TB-500 |
|---|---|---|
| Certificate of analysis | Lot identity, purity, and analytical method | Identity of a fragment peptide cannot be assumed from appearance |
| Mass spectrometry data | Molecular mass consistent with the stated fragment | Confirms the correct fragment rather than a related peptide |
| HPLC trace | Purity profile and impurity distribution | Purity affects interpretation of any in vitro work |
| Sequence confirmation | Amino acid order of the fragment | The evidence block does not supply a sequence; the lot record must |
| Storage and handling sheet | Recommended storage conditions for the lyophilised powder | Peptide stability depends on storage; conditions are lot- and format-specific |
TB-500 sourcing and price considerations
Price for a research peptide is not a single number; it is a function of lot size, purity grade, and the documentation supplied with the lot. The evidence block does not contain pricing data, and no price is quoted here. What can be said is that the two variables a laboratory can compare across suppliers are the stated purity and the completeness of the lot record. A lower-priced lot with an incomplete analytical record is not equivalent to a higher-priced lot with a complete one, because the two cannot be compared on identity.
- Compare lots on stated purity and analytical method, not on price alone.
- Request the certificate of analysis for the specific lot before ordering.
- Confirm that mass spectrometry and HPLC data accompany the lot.
- Confirm storage and handling instructions for the lyophilised format.
- Treat any supplier claim of a therapeutic effect as outside the scope of a research-supply transaction.
TB-500 and research-use-only framing
TB-500 is supplied for laboratory research. The indexed record describes an investigational Phase 1/2 study in adults with stable ASCVD [1]; it does not describe an approved product, and it does not report results. A research-supply catalogue entry is not a clinical monograph, and the two should not be conflated.
If you are reading this for personal health reasons
This material is sold for laboratory research only, and we do not provide dosing or medical guidance of any kind. Nothing on this page is medical advice, and no outcome is promised or implied. If you are considering a compound for yourself, speak to a licensed clinician.
Sources
- [1] TB-500 (Thymosin Beta 4 17-23 Fragment) for Cardiovascular Biomarkers in Stable ASCVD — ClinicalTrials.gov